Preoperative [ 18 F]fluoro-PEG-folate PET/CT in advanced stage epithelial ovarian cancer: A safety and feasibility study.

Purpose: The selection for either primary or interval cytoreductive surgery (CRS) in patients with epithelial ovarian cancer (EOC) is currently based on imaging techniques like computed tomography (CT), [ ¹⁸ F]fluorodeoxyglucose-positron emission tomography ([ ¹⁸ F]FDG-PET), diffusion-weighted magnetic resonance imaging (DW-MRI) and/or diagnostic laparoscopy, but these have limitations. Folate receptor (FR)-targeted PET/CT imaging, using [ ¹⁸ F]fluoro-PEG-folate, could improve preoperative assessment, potentially reducing unnecessary laparotomies. This paper presents the first experience with [ ¹⁸ F]fluoro-PEG-folate PET/CT imaging in advanced stage EOC, focusing on safety, tolerability, and feasibility for reflecting the extent of disease.
Methods: Tolerability and safety were monitored after administration of the [ ¹⁸ F]fluoro-PEG-folate tracer by measurements of vital function parameters (blood pressure, heart rate, peripheral oxygen saturation, respiratory rate, and temperature). In addition, (serious) adverse events were recorded. Disease burden was quantified using the Peritoneal Cancer Index (PCI) score on preoperative [ ¹⁸ F]fluoro-PEG-folate PET/CT and during surgery. PCI scores were compared with intraoperative findings, considering histopathologic results as the gold standard. Tissue specimens were stained for FRα and FRβ. Relative uptake of the radiotracer by EOC lesions and other tissues was quantified using body weighted standardized uptake values (SUV).
Results: The study was terminated prematurely during the interim analysis after inclusion of eight patients of whom five had completed the study protocol. Although [ ¹⁸ F]fluoro-PEG-folate demonstrated safety, efficacy for tumor-specific imaging was limited. Despite clear FRα overexpression, low tracer uptake was observed in EOC lesions, contrasting with high uptake in healthy tissues, posing challenges in specificity and accurately assessing tumor burden.
Conclusions: Overall, while [ ¹⁸ F]fluoro-PEG-folate was well-tolerated, its clinical utility in the preoperative assessment of the extent of disease in EOC was limited. This highlights the need for further research in developing targeted imaging agents for optimal detection of EOC metastases.
Trial Registration: Clinicaltrials.gov, NCT05215496. Registered 31 January 2022.
Competing Interests: Declaration of competing interest A.D. Windhorst is editor-in-chief of Nuclear Medicine & Biology and was not involved in the editorial review or the decision to publish this article. All other authors have no relevant financial or non-financial interests to disclose.
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)